Johns Hopkins Sjögren’s Center

Home / Research / NOVARTIS VAY736: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s Syndrome

NOVARTIS VAY736: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s Syndrome

Overview

This clinical drug trial was conducted with active Sjögren’s disease patients to test the efficacy and safety of the pharmaceutical in that population. As there are no FDA-approved medications specifically for Sjögren’s disease, researchers are constantly working to unveil new medications, therapies and diagnostic tools for Sjögren’s disease and its symptoms.

Key Facts

  • Status: Completed
  • Principal Investigator: Thomas Grader-Beck, MD
  • Sponsor: Novartis Pharmaceuticals
  • Location: Johns Hopkins Jerome L. Greene Sjögren’s Center

Study Design
This study included individuals between 18-65 years of age and tested a trial drug for patients with active Sjögren’s disease.

Results
To view results and ongoing discoveries related to this trial, see the Clinical Trials Page.

Impact
This research has provided valuable knowledge about Sjögren’s disease that is likely to facilitate the development of better treatments.

Use of this Site

All information contained within the Johns Hopkins Jerome L. Green Sjogren’s Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.